Roche CEO Daniel O’Day has been named as the new Chairman and CEO of Gilead Sciences, in an appointment effective March 1 2019.
Mr O’Day has held his current senior position at Roche since 2012 and previously led Roche Diagnostics.
His career spans three decades of diverse leadership roles across North America, Asia Pacific and Europe.
Greg Alton as been appointed by the Gilead Board to act as interim CEO from January 1 2019 until Mr O’Day’s appointment takes effect.
“Following a comprehensive search, the Board became convinced that Dan is the right leader to bring Gilead into the future,” said Chairman John C. Martin, who is stepping down on March 1.
“He is uniquely qualified to take on this role given his track record of success in highly scientific and competitive therapeutic areas, deep understanding of the evolving healthcare environment around the world, and unwavering commitment to driving innovation across all aspects of a business, which will serve Gilead and our stakeholders well.
“Additionally, Dan brings expertise and values that are aligned with our organization, and I, along with Gilead’s entire Board, am confident in his ability to work alongside our talented leadership team and deliver on our ambitious goals.”